Eric joined Samsara BioCapital as a Venture Partner in 2024. He brings over two decades of leadership, operating and business development experience in the biotechnology industry. Most recently, Eric was President and CEO of Chinook Therapeutics, a biotechnology company focused on developing precision medicines for kidney disease that was acquired by Novartis for $3.5 billion in 2023. Previously, he was President and CEO of Silverback Therapeutics, and prior to that held positions of increasing responsibility over more than 15 years at Seagen, including Chief Operating Officer. During his career, he has been directly involved in raising more than $2 billion in equity capital, and led negotiation of corporate alliances with many leading biotechnology and pharmaceutical companies.
Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He currently serves on the boards of directors of Structure Therapeutics, (Nasdaq: GPCR), Janux Therapeutics (Nasdaq: JANX) and several private biotechnology companies.